Identification of the shortest Aβ-peptide generating highly specific antibodies against the C-terminal end of amyloid-β42

Vaccine

Volumn 29, Issue 17, 2011, Pages 3260-3269

  Axelsen, Trine Veje ^a,b   Holm, Arne ^a   Christiansen, Gunna ^a   Birkelund, Svend ^a  

^a Loke Diagnostics ApS   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Amyloid; Alzheimer's disease; Antigen construct

Indexed keywords

ADJUVANT; ALZHEIMER DISEASE VACCINE; AMINO ACID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[37-42]; ANTIBODY; DIMER; EPITOPE; IMMUNOGLOBULIN G1 ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; LIGAND; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BRAIN TISSUE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; COVALENT BOND; HUMAN; HUMAN TISSUE; IMMUNIZATION; INFLAMMATION; MOUSE; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SENILE PLAQUE; T LYMPHOCYTE; TECHNOLOGY; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; AMYLOID BETA-PEPTIDES; ANIMALS; EPITOPES; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; T-LYMPHOCYTES;

EID: 79954575340     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.026     Document Type: Article

References (54)

1. Bonilla F.A., Oettgen H.C. Adaptive immunity. J Allergy Clin Immunol 2010, 125(2 Suppl 2):S33-40.
2. Haro I., Gomara M.J. Design of synthetic peptidic constructs for the vaccine development against viral infections. Curr Protein Pept Sci 2004, 5(6):425-433.
3. Otvos L. Synthesis of a multivalent, multiepitope vaccine construct. Methods Mol Biol 2008, 494:263-273.
4. Ghochikyan A. Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. CNS Neurol Disord Drug Targets 2009, 8(2):128-143.
5. Tabira T. Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J Exp Med 2010, 220(2):95-106.
6. Lemere C.A., Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy?. Nat Rev Neurol 2010, 6(2):108-119.
7. Cribbs D.H., Ghochikyan A., Vasilevko V., Tran M., Petrushina I., Sadzikava N., et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 2003, 15(4):505-514.
8. Town T., Tan J., Sansone N., Obregon D., Klein T., Mullan M. Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42. Neurosci Lett 2001, 307(2):101-104.
9. Axelsen T.V., Holm A., Birkelund S., Christiansen G., Ploug M., Holm I.E. Specific recognition of the C-terminal end of A beta 42 by a high affinity monoclonal antibody. Mol Immunol 2009, 46(11-12):2267-2273.
10. Levites Y., Das P., Price R.W., Rochette M.J., Kostura L.A., McGowan E.M., et al. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 2006, 116(1):193-201.
11. Asami-Odaka A., Obayashi-Adachi Y., Matsumoto Y., Takahashi H., Fukumoto H., Horiguchi T., et al. Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease. Neurodegener Dis 2005, 2(1):36-43.
12. Monsonego A., Maron R., Zota V., Selkoe D.J., Weiner H.L. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A 2001, 98(18):10273-10278.
13. Schenk D., Seubert P., Ciccarelli R.B. Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier. DNA Cell Biol 2001, 20(11):679-681.
14. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400(6740):173-177.
15. Klein W.L., Stine W.B., Teplow D.B. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 2004, 25(5):569-580.
16. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 2003, 100(18):10417-10422.
17. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004, 5(9):677-685.
18. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42 (43). Neuron 1994, 13(1):45-53.
19. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325(6106):733-736.
20. Joachim C.L., Duffy L.K., Morris J.H., Selkoe D.J. Protein chemical and immunocytochemical studies of meningovascular beta-amyloid protein in Alzheimer's disease and normal aging. Brain Res 1988, 474(1):100-111.
21. Purkerson J., Isakson P. A two-signal model for regulation of immunoglobulin isotype switching. FASEB J 1992, 6(14):3245-3252.
22. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986. J Immunol 2005, 175(1):5-14.
23. Finkelman F.D., Svetic A., Gresser I., Snapper C., Holmes J., Trotta P.P., et al. Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice. J Exp Med 1991, 174(5):1179-1188.
24. Holm A., Jorgensen R.M., Ostergaard S., Theisen M. Ligand-presenting assembly: a method for C- and N-terminal antigen presentation. J Pept Res 2000, 56(2):105-113.
25. Panina-Bordignon P., Tan A., Termijtelen A., Demotz S., Corradin G., Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 1989, 19(12):2237-2242.
26. Demotz S., Lanzavecchia A., Eisel U., Niemann H., Widmann C., Corradin G. Delineation of several DR-restricted tetanus toxin T cell epitopes. J Immunol 1989, 142(2):394-402.
27. Swerdlow R.D., Ebert R.F., Lee P., Bonaventura C., Miller K.I. Keyhole limpet hemocyanin: structural and functional characterization of two different subunits and multimers. Comp Biochem Physiol B Biochem Mol Biol 1996, 113(3):537-548.
28. Lambrecht B.N., Kool M., Willart M.A., Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009, 21(1):23-29.
29. Kensil C.R., Patel U., Lennick M., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 1991, 146(2):431-437.
30. Birkelund S., Larsen B., Holm A., Lundemose A.G., Christiansen G. Characterization of a linear epitope on Chlamydia trachomatis serovar L2 DnaK-like protein. Infect Immun 1994, 62(5):2051-2057.
31. Juul N., Jensen H., Hvid M., Christiansen G., Birkelund S. Characterization of in vitro chlamydial cultures in low-oxygen atmospheres. J Bacteriol 2007, 189(18):6723-6726.
32. Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006, 112(4):389-404.
33. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41(4):479-486.
34. Croxtall J.D., Keating G.M. Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV). Paediatr Drugs 2009, 11(5):349-357.
35. Snapper C.M., Mond J.J. Towards a comprehensive view of immunoglobulin class switching. Immunol Today 1993, 14(1):15-17.
36. Stavnezer J., Immunoglobulin class switching. Curr Opin Immunol 1996, 8(2):199-205.
37. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002, 3(10):824-828.
38. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003, 9(4):448-452.
39. Sigurdsson E.M., Scholtzova H., Mehta P.D., Frangione B., Wisniewski T. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 2001, 159(2):439-447.
40. Sigurdsson E.M., Knudsen E., Asuni A., Fitzer-Attas C., Sage D., Quartermain D., et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci 2004, 24(28):6277-6282.
41. Solomon B., Koppel R., Hanan E., Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A 1996, 93(1):452-455.
42. Solomon B., Koppel R., Frankel D., Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A 1997, 94(8):4109-4112.
43. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6(8):916-919.
44. Naslund J., Schierhorn A., Hellman U., Lannfelt L., Roses A.D., Tjernberg L.O., et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A 1994, 91(18):8378-8382.
45. Liu K., Solano I., Mann D., Lemere C., Mercken M., Trojanowski J.Q., et al. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. Acta Neuropathol 2006, 112(2):163-174.
46. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A 2003, 100(4):2023-2028.
47. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408(6815):982-985.
48. Das P., Howard V., Loosbrock N., Dickson D., Murphy M.P., Golde T.E. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci 2003, 23(24):8532-8538.
49. Spazierer D., Skvara H., Dawid M., Fallahi N., Gruber K., Rose K., et al. T helper 2 biased de novo immune response to Keyhole Limpet Hemocyanin in humans. Clin Exp Allergy 2009, 39(7):999-1008.
50. Gilewski T., Adluri S., Ragupathi G., Zhang S., Yao T.J., Panageas K., et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000, 6(5):1693-1701.
51. Schenkman E., Lamm D.L. Superficial bladder cancer therapy. ScientificWorldJournal 2004, 4(Suppl1):387-399.
52. Jennings V.M. Review of selected adjuvants used in antibody production. ILAR J 1995, 37(3):119-125.
53. Bockova J., Elias D., Cohen I.R. Treatment of NOD diabetes with a novel peptide of the hsp60 molecule induces Th2-type antibodies. J Autoimmun 1997, 10(4):323-329.
54. Lemere C.A. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Prog Brain Res 2009, 175:83-93.